SCHEMBL2095657

SCHEMBL2095657

FC(F)(F)Oc1ccc(C=C2CC[N]CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.49
PIM2 Q9P1W9 2/20 0.49
KDM4E B2RXH2 1/20 0.43
OGA O60502 1/20 0.41
NISCH Q9Y2I1 1/20 0.41
RXRA P19793 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.35
EPHX2 P34913 1/20 0.35
SCN5A Q14524 1/20 0.35
CYP2D6 P10635 1/20 0.35
PDE2A O00408 1/20 0.34
KDM1A O60341 1/20 0.34
RCOR1 Q9UKL0 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 1/20 0.34
MAOB P27338 1/20 0.33
AOC3 Q16853 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2093061 0.79 CYP1A2 (0.49) PIM1PIM2
Hydrochloric Acid SCHEMBL18280002 0.78 PIM2 (0.51) PIM1PIM2KDM4EOGANISCH
SCHEMBL13503848 0.78 PIM1 (0.48) PIM1PIM2KDM4EOGAGAA
SCHEMBL2056135 0.77 ALDH1A1 (0.51) PIM1PIM2KDM4EOGAEPHX2
SCHEMBL13503717 0.74 PIM1 (0.44) PIM1PIM2KDM4EOGAEPHX2
SCHEMBL2090365 0.72 AKR1C3 (0.43) PIM1PIM2GAAMAPTMAOB
SCHEMBL13790221 0.71 CYP2D6 (0.50) PIM1PIM2KDM4EMAPTEPHX2
SCHEMBL2092050 0.71 PIM1 (0.49) PIM1PIM2KDM4ENISCHGAA
SCHEMBL254957 0.69 MAPT (0.56) PIM1PIM2KDM4ENISCHGAA
SCHEMBL15117409 0.69 PIM1 (0.47) PIM1PIM2KDM4ENISCHGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 PIM1 3429/4885PIM2 2138/4885KDM4E 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.